Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
For a patient with locally advanced rectal cancer, would positive ctDNA after total neoadjuvant therapy affect your management?
Would you consider additional chemotherapy post-operatively?
Related Questions
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
What are the treatment options for patients with duodenal cancer who have progressed on FOLFIRINOX?
How do you integrate immunotherapy as a part of neoadjuvant treatment for MSI high stage III gastric carcinoma?
Which patients with metastatic HER2 negative, PD-L1 <1% esophageal cancer patients, would you utilize paclitaxel/ramucirumab maintenance?
Would you ever consider treatment without tissue diagnosis for a gastrointestinal neuroendocrine metastatic tumor based on a positive dotatate scan alone?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
How do you best incorporate use of filgrastim/pegfilgrastim in capecitabine based regimens?
Would you use bevacizumab in a metastatic RAS-mutant colon cancer, if the patient had a colon perforation that was resected?